Adcetris Interactions
There are 647 drugs known to interact with Adcetris (brentuximab), along with 8 disease interactions, and 2 alcohol/food interactions. Of the total drug interactions, 67 are major, and 580 are moderate.
- View all 647 medications that may interact with Adcetris
- View Adcetris alcohol/food interactions (2)
- View Adcetris disease interactions (8)
Most frequently checked interactions
View interaction reports for Adcetris (brentuximab) and the medicines listed below.
- Adcirca (tadalafil)
- Adriamycin (doxorubicin)
- bleomycin
- Blincyto (blinatumomab)
- Braftovi (encorafenib)
- Celebrex (celecoxib)
- CellCept (mycophenolate mofetil)
- Corlanor (ivabradine)
- Cosentyx (secukinumab)
- Cymbalta (duloxetine)
- Cytoxan (cyclophosphamide)
- Emgality (galcanezumab)
- Empliciti (elotuzumab)
- enalapril
- Entyvio (vedolizumab)
- Esbriet (pirfenidone)
- Hemlibra (emicizumab)
- Idhifa (enasidenib)
- Imbruvica (ibrutinib)
- Kalydeco (ivacaftor)
- Kynamro (mipomersen)
- Letairis (ambrisentan)
- Ocrevus (ocrelizumab)
- Ofev (nintedanib)
- Oncovin (vincristine)
- prednisone
- Ravicti (glycerol phenylbutyrate)
- Repatha (evolocumab)
- Stribild (cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil)
- Tecfidera (dimethyl fumarate)
Adcetris alcohol/food interactions
There are 2 alcohol/food interactions with Adcetris (brentuximab).
Adcetris disease interactions
There are 8 disease interactions with Adcetris (brentuximab) which include:
- infections
- tumor lysis syndrome
- hepatotoxicity
- hyperglycemia
- peripheral neuropathy
- pulmonary toxicity
- renal impairment
- Brentuximab vedotin -GI events
Report options
More about Adcetris (brentuximab)
- Adcetris consumer information
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: CD30 monoclonal antibodies
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Decadron
Decadron is used for addison's disease, adrenal insufficiency, adrenocortical insufficiency ...
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Revlimid
Revlimid is used to treat types of multiple myeloma, mantle cell lymphoma, follicular lymphoma and ...
Nivolumab
Nivolumab (brand name Opdivo) is an immunotherapy treatment that treats many cancers, such as ...
Cyclophosphamide
Cyclophosphamide systemic is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia ...
Rituximab
Rituximab infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Pembrolizumab
Pembrolizumab (Keytruda) is a monoclonal antibody cancer medicine used to treat
Dexamethasone
Dexamethasone is used to treat inflammatory conditions such as allergies, skin conditions ...
Methotrexate
Methotrexate is used to treat certain types of cancer of the breast, skin, head and neck, or lung ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.